Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
| 28.97 | |
| 30.07 | |
| - | |
| 31.61 | |
| 28.88 | |
| 0.6792-33.77 | |
| 850 M | |
| 29 350 K | |
| 3 224 K | |
| -0.54 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President,...
Began trading on Nasdaq under the ticker symbol DNTH following the successful completion of our merger with Magenta Therapeutics Completed concurrent $72 million financingwith a syndicate of leading ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
